Company / EPS (Diluted)
Theravance Biopharma, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.15
FY2025
5-year range
-$4.46 / $11.85
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#94 of 204
Health Care
What the data says
At $-1.15, Theravance Biopharma, Inc.'s eps (diluted) ranks #94 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-7.46 in FY2016 to $11.85 in FY2023.
Based on SEC 10-K filings.
-1.15 in FY2025.
Declined from $11.85 to $-1.15 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#94 of 204 in Health CareTop 46% of 204This company -$1.15 Sector average -$0.89
▼
-29.8% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 15.0% year-over-year.
- Ranks #94 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2023.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.15 | -15.0% |
| FY2024 | -$1.00 | -108.4% |
| FY2023 | $11.85 | +365.7% |
| FY2022 | -$4.46 | -4.9% |
| FY2021 | -$4.25 | -6.5% |
| FY2020 | -$3.99 | +26.8% |
| FY2019 | -$5.45 | -27.9% |
| FY2018 | -$4.26 | +20.2% |
| FY2017 | -$5.34 | +28.4% |
| FY2016 | -$7.46 | -51.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026